Roivant Sciences CEO Eric Venker Buys 200,000 Shares at $3.85—A Signal of Confidence Amid Volatile Biotech Market
Roivant insider trading: Venker Eric’s recent $3.85 purchases signal confidence in the company’s biotech pipeline, offering investors insight into leadership’s bullish stance and strategic balance of liquidity and long‑term commitment.
3 minutes to read